Cargando…
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank
A plateau in treatment effect can be seen for the current ‘one-size-fits-all’ approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment (TME) is largely immunosuppressed, however a subgroup of patient...
Autores principales: | Lonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo, Barbour, Andrew P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642165/ https://www.ncbi.nlm.nih.gov/pubmed/37965317 http://dx.doi.org/10.3389/fimmu.2023.1220129 |
Ejemplares similares
-
ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022) -
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
por: Aoude, Lauren G., et al.
Publicado: (2020) -
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
por: M. Naeini, Marjan, et al.
Publicado: (2023) -
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
por: Mercieca-Bebber, R., et al.
Publicado: (2022) -
Generalising uncertainty improves accuracy and safety of deep learning analytics applied to oncology
por: MacDonald, Samual, et al.
Publicado: (2023)